Professor Parry Guilford
The inactivation of tumour suppressor genes is the most common of all genetic events in cancer but not one that can be targeted by conventional therapy, because the tumour suppressor protein is lost from the cancer cell.
Inhibiting the human GH receptor with small molecule antagonists
Dr Jo Perry
Localised production of growth hormone (GH) is detectable in a variety of different human cancers, including breast cancer, and this is associated with an increased risk of metastasis and reduced survival for breast cancer patients.
SHON as a novel biomarker predicting endocrine therapy response in breast cancer
Dr Dong Xu-Lui
Breast cancer affects 1 in 9 New Zealand women. Anti-estrogens such as tamoxifen have been used to treat estrogen receptor positive (ER+) breast cancer and reduce the annual death rate by approximately one third.
Targeting the immune response to improve outcomes in ER+ve breast cancer
Dr Anita Dunbier
Every year, more than 2000 New Zealand women are diagnosed with oestrogen receptor positive breast cancer.